Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer

Journal of Clinical Oncology

Volumn 23, Issue 7, 2005, Pages 1455-1462

  Reesink Peters, Nathalie ^a   van der Velden, Jacobus ^a   Ten Hoor, Klaske A ^a   Boezen, H Marike ^a   De Vries, Elisabeth G E ^a   Schilthuis, Marten S ^a   Mourits, Marian J E ^a   Nijman, Hans W ^a   Aalders, Jan G ^a   Hollema, Harry ^a   Pras, Elisabeth ^a   Duk, Jitze M ^a   van der Zee, Ate G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; TUMOR ANTIGEN; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA RELATED ANTIGEN; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UTERINE CERVIX CANCER; BLOOD; COHORT ANALYSIS; DECISION MAKING; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; UTERINE CERVIX TUMOR;

ADULT; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DECISION MAKING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SERPINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 20144370423     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.123     Document Type: Article

References (27)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64,1, 1999
2. Finan MA, DeCesare S, Fiorica JV, et al: Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: Does the new staging system predict morbidity and survival? Gynecol Oncol 62:139-147, 1996
3. National Institutes of Health Consensus Development Conference statement on cervical cancer. April 1-3, 1996. Gynecol Oncol 66:351-361, 1997
4. Landoni F, Maneo A, Colombo A, et al: Randomised study of radical surgery versus radiotherapy for stage Ib- IIa cervical cancer. Lancet 350:535-540, 1997
5. Duk JM, Groenier KH, de Bruijn HW, et al: Pretreatment serum squamous cell carcinoma antigen: A newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 14: 111-118, 1996
6. Bolger BS, Dabbas M, Lopes A, et al: Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol 65:309-313, 1997
7. Juang CM, Wang PH, Yen MS, et al: Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol Oncol 76:103-106, 2000
8. Strauss HG, Laban C, Lautenschlager C, et al: SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur J Cancer 38:1987-1991, 2002
9. Gaarenstroom KN, Kenter GG, Bonfrer JM, et al: Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol 77:164-170, 2000
10. Lin H, ChangChien CC, Huang EY, et al: The role of pretreatment squamous cell carcinoma antigen in predicting nodal metastasis in early stage cervical cancer. Acta Obstet Gynecol Scand 79:140-144, 2000
11. Takeshima N, Hirai Y, Katase K, et al: The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer. Gynecol Oncol 68:263-266, 1998
12. Kurman RJ, Norris HJ, Wilkinson E: Tumors of the cervix, vagina, and vulva: Tumors of the cervix, in Rosai J (ed): Atlas of Tumor Pathology. Washington, DC, Armed Forces Institute of Pathology, 1992 (pp 37-139)
13. Maruo T, Shibata K, Kimura A, et al: Tumor-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Serial determinations and tissue localization. Cancer 56:302-308, 1985
14. Hacker NF: Cervical cancer, in Berek JS, Hacker NF (eds): Practical Gynecologic Oncology. Philadelphia, PA, Lippincott Williams & Wilkins, 2000 (345-407)
15. Friedlander M: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 7:342-347, 2002
16. Look KY, Rocereto TF: Relapse patterns in FIGO stage IB carcinoma of the cervix. Gynecol Oncol 38:114-120, 1990
17. Sedlis A, Bundy BN, Rotman MZ, et al: A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 73:177-183, 1999
18. de Roda H, Walboomers JM, Meijer CJ, et al: Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. Int J Cancer 56:802-806, 1994
19. Grigsby PW: Stage IB1 vs IB2 carcinoma of the cervix: Should the new FIGO staging system define therapy? Gynecol Oncol 62:135-136, 1996
20. Morris M: Early cervical carcinoma: Are two treatments better than one? Gynecol Oncol 54:1-3, 1994
21. Bloss JD, Berman ML, Mukhererjee J, et al: Bulky stage IB cervical carcinoma managed by primary radical hysterectomy followed by tailored radiotherapy. Gynecol Oncol 47:21-27, 1992
22. Burke TW: Treatment options in stage IB cervical cancer: Radical hysterectomy and radiotherapy. Semin Radiat Oncol 4:34-40, 1994
23. Covens A, Rosen B, Murphy J, et al: Changes in the demographics and perioperative care of stage IA(2)/IB(1) cervical cancer over the past 16 years. Gynecol Oncol 81:133-137, 2001
24. Chou CY, Wang ST, Kuo HC, et al: Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer. Cancer 74:2497-2501, 1994
25. Boss EA, Barentsz JO, Massuger LF, et al. The role of MR imaging in invasive cervical carcinoma. Eur Radiol 10:256-270, 2000
26. Guyatt GH, Lefcoe M, Walter S, et al: Interobserver variation in the computed tomographic evaluation of mediastinal lymph node size in patients with potentially resectable lung cancer. Canadian Lung Oncology Group. Chest 107:116-119, 1995
27. Stafira JS, Sonnad JR, Yuh WT, et al: Qualitative assessment of cervical spinal stenosis: Observer variability on CT and MR images. AJNR Am J Neuroradiol 24:766-769, 2003